Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects.

International journal of molecular sciences - 27 Mar 2021

Mishra Rosalin, Patel Hima, Alanazi Samar, Kilroy Mary Kate, Garrett Joan T

Abstract excerpt

The phospatidylinositol-3 kinase (PI3K) pathway is a crucial intracellular signaling pathway which is mutated or amplified in a wide variety of cancers including breast, gastric, ovarian, colorectal, prostate, glioblastoma and endometrial cancers. PI3K signaling plays an important role in cancer cell survival, angiogenesis and metastasis, making it a promising therapeutic target. There are several ongoing and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Class I Phosphatidylinositol 3-Kinases
Share to Clinical Trials as Topic

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Drug-Related Side Effects and Adverse Reactions

Share to Neovascularization, Pathologic

Share to Phosphatidylinositol 3-Kinases

Share to Phosphoinositide-3 Kinase Inhibitors

Share to RNA, Untranslated

Share to TOR Serine-Threonine Kinases

Source

Open in PubMed Open full text

Identifiers

PMID: 33801659
DOI: 10.3390/ijms22073464
PMCID: PMC8037248

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects.PMID 33801659Read ↗

Targeting PI3K in cancer: mechanisms and advances in clinical trialsSemantic proximity Read ↗

Current State and Future Challenges for PI3K Inhibitors in Cancer TherapySemantic proximity Read ↗

Phosphatidylinositol 3-kinase (PI3K) inhibitors: a recent update on inhibitor design and clinical trials (2016-2020).Semantic proximity Read ↗

Strategies and techniques for preclinical therapeutic targeting of PI3K in oncology: where do we stand in 2024?Semantic proximity Read ↗

Targeting PI3K family with small-molecule inhibitors in cancer therapy: current clinical status and future directionsSemantic proximity Read ↗

Targeting PI3K in Cancer: Any Good News?Semantic proximity Read ↗

PI3K inhibitors for cancer treatment: where do we stand?Semantic proximity Read ↗

Challenges in the clinical development of PI3K inhibitors.Semantic proximity Read ↗

Advances in subunits of PI3K class I in cancer.Semantic proximity Read ↗

Challenges for the Clinical Development of PI3K Inhibitors: Strategies to Improve Their Impact in Solid TumorsSemantic proximity Read ↗

New phosphatidylinositol 3-kinase inhibitors for cancer.Semantic proximity Read ↗

Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.